For example, targeted antibody therapies for lung cancer with mutant EGFR oncogenes include necitumumab (Portrazza, Eli Lilly and Co.), cetuximab (Erbitux, Eli Lilly and Co.)and amivantamab-vmjw (Rybrevant, Janssen Biotech). This evidence concerns the gene EGFR and lung carcinoma.